Exit strategies in Europe

Article Abstract:

Two German biotech company executives, Jean-Yves Nothais, a French venture capital fund manager and Patrik Frei, a Swiss valuation expert explore their views on the investment status in Europe for biotech companies seeking exits with reference to the factors influencing exit strategy. They suggest that European biotech companies must focus on building investor visibility, pharma collaborations and consolidation to boost their chances of successful exits to overcome legal, cultural and linguistic barriers.

Evaluation, Exit strategies (Management), Discussion

---

Danish biotech outperforms its European counterparts

Article Abstract:

Danish biotech companies raised unprecedented amounts of venture capital, opened the window for initial public offerings and lured investors with follow-up offering in the fiscal 2006 outpacing its neighbors in Scandinavia and Europe. The secret of the country's biotech sector might lie in the strong research base and the support that local pharma companies offer in forming, funding and collaborating with biotech being a source of skilled management to run them.

Netherlands, International aspects

---

Building a business: Key ingredients for success in Europe

Article Abstract:

The views of biotechnologists towards the development of biotech industry in Europe are discussed in the article. A large pool of qualified people, infrastructure, university participation and substantial funding are the key factors for establishing the biotech industry.

Business success, Industry overview

Similar abstracts:

• Abstracts: Scrutinising business banking. By appointment to the spies. Big Four split over OFR
• Abstracts: Capital structure policies in Europe: survey evidence. Multi-period stochastic optimization models for dynamic asset allocation
• Abstracts: Research issues in building brand equity and global brands in the pc market. Internationalization of services brands: the role of leadership during the internal brand building process
• Abstracts: UK bank services for small business: How competitive is the market? A more complete conceptual framework for SME finance
• Abstracts: Empowering microarrays in the regulatory setting. Evaluation of DNA microarray results with quantitative gene expression platforms

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.